Institution
Atlantic Health System
Healthcare•Morristown, New Jersey, United States•
About: Atlantic Health System is a healthcare organization based out in Morristown, New Jersey, United States. It is known for research contribution in the topics: Catheter ablation & Antiarrhythmic agent. The organization has 277 authors who have published 299 publications receiving 6594 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This data indicates that treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies such as BRAF/MEK inhibitors (if BRAF-V600E muta...
Abstract: 2518Background: Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies such as BRAF/MEK inhibitors (if BRAF-V600E muta...
29 citations
••
Beth Israel Deaconess Medical Center1, Harvard University2, Hebron University3, Rambam Health Care Campus4, Translational Genomics Research Institute5, Hospital Universitario La Paz6, University of Navarra7, New York University8, Atlantic Health System9, Hospital General Universitario Gregorio Marañón10, Tel Aviv Sourasky Medical Center11, Hebrew University of Jerusalem12, Merck & Co.13, Cornell University14
TL;DR: In this article, the authors evaluated the safety and efficacy of motixafortide and pembrolizumab combined to chemotherapy in patients with de novo metastatic PDAC and disease progression on front-line gemcitabine-based therapy.
Abstract: Purpose: Pancreatic ductal adenocarcinoma (PDAC) is largely unresponsive to checkpoint inhibitors. Blockade of the CXCR4/CXCL12 axis increases intratumoral trafficking of activated T cells while restraining immunosuppressive elements. This study evaluates dual blockade of CXCR4 and PD1 with chemotherapy in PDAC. Experimental Design: Multicenter, single arm, phase II study to evaluate the safety and efficacy of motixafortide and pembrolizumab combined to chemotherapy in patients with de novo metastatic PDAC and disease progression on front-line gemcitabine-based therapy (NCT02826486). Subjects received a priming phase of motixafortide daily on days 1-5, followed by repeated cycles of motixafortide twice a week, pembrolizumab every 3 weeks, nanoliposomal irinotecan, fluorouracil and leucovorin every 2 weeks (NAPOLI-1 regimen). The primary objective was objective response rate (ORR). Secondary objectives included overall survival (OS), progression-free survival (PFS), disease control rate, safety and tolerability. Results: A total of 43 patients were enrolled. The objective response rate according to RECISTv1.1 was 21.1% with confirmed ORR of 13.2%. The disease control rate was 63.2% with median duration of clinical benefit of 5.7 months. In the intention to treat population, median PFS was 3.8 months and median OS was 6.6 months. The triple combination was safe and well tolerated with toxicity comparable to the NAPOLI-1 regimen. Notably, the incidence of grade 3 or higher neutropenia and infection were 7%, lower than expected for this chemotherapy regimen. Conclusion: Triple combination of motixafortide, pembrolizumab and chemotherapy was safe, well tolerated and showed signs of efficacy in a population with poor prognosis and aggressive disease.
28 citations
••
TL;DR: Results of pilot clinical studies of hybrid therapy are encouraging and involve drugs, devices and ablation techniques in varying permutations and considerations in implementation of these algorithms include staged or simultaneous interventions and a right versus left heart strategy.
Abstract: Rhythm control methods have not shown superior outcomes to rate control strategies in atrial fibrillation. Newer approaches to rhythm control employ "hybrid" therapies combining pharmacologic and non pharmacologic interventions. Pathophysiologic insights into mechanisms of atrial fibrillation (AF) suggest that arrhythmogenesis is due to interactions of multiple triggering rhythms and a complex electrophysiologic substrate resulting in the emergence of multiple tachyarrhythmias, often in disparate locations that may coexist in time. Thus, an "hybrid" therapy prescription is more likely to address several of the etiologic factors culminating in clinical AF. Results of pilot clinical studies of hybrid therapy are encouraging and involve drugs, devices and ablation techniques in varying permutations. Hybrid therapy algorithms using right heart procedures can improve efficacy with potentially lower risk. Considerations in implementation of these algorithms include staged or simultaneous interventions and a right versus left heart strategy. The parallel with the current coronary disease management paradigm is obvious and relevant.
28 citations
01 Nov 2014
TL;DR: Aβ concentration was low to undetectable in splenic lymphoid tissue and several other control tissues including heart, lung, liver, kidneys and intestine of the same animals, strongly suggesting that Aβ peptides in lymph nodes are derived from the brain.
Abstract: Evidence has shown that lymphatic drainage contributes to removal of debris from the brain but its role in the accumulation of amyloid β peptides (Aβ) has not been demonstrated. We examined the levels of various forms of Aβ in the brain, plasma and lymph nodes in a transgenic model of Alzheimer's disease (AD) at different ages. Herein, we report on the novel finding that Aβ is present in the cervical and axillary lymph nodes of AD transgenic mice and that Aβ levels in lymph nodes increase over time, mirroring the increase of Aβ levels observed in the brain. Aβ levels in lymph nodes were significantly higher than in plasma. At age 15.5months, there was a significant increase of monomeric soluble Aβ40 (p=0.003) and Aβ42 (p=0.05) in the lymph nodes over the baseline values measured at 6months of age. In contrast, plasma levels of Aβ40 showed no significant changes (p=0.68) and plasma levels Aβ42 significantly dropped (p=0.02) at the same age. Aβ concentration was low to undetectable in splenic lymphoid tissue and several other control tissues including heart, lung, liver, kidneys and intestine of the same animals, strongly suggesting that Aβ peptides in lymph nodes are derived from the brain.
28 citations
••
University of Louisville1, University of Colorado Denver2, University of Colorado Boulder3, Yale University4, University of Florida Health5, Mayo Clinic6, New York University7, Atlantic Health System8, University of Navarra9, Cambridge University Hospitals NHS Foundation Trust10, Mount Sinai Hospital11, The Royal Marsden NHS Foundation Trust12, University of Pittsburgh13
TL;DR: A small number of patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies have responded to adoptive cell therapy using tumor-infiltratin, and this data indicates that this therapy may be a viable option for these patients.
Abstract: 10006Background: Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltratin...
27 citations
Authors
Showing all 279 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kurt A. Jaeckle | 57 | 169 | 14597 |
Donald E. Casey | 56 | 102 | 62844 |
Sanjeev Saksena | 44 | 169 | 6463 |
John J. Halperin | 42 | 145 | 9806 |
Linda D. Gillam | 39 | 102 | 9249 |
Missak Haigentz | 39 | 129 | 4217 |
Ian J. Griffin | 35 | 107 | 3998 |
Philip T. Levy | 30 | 106 | 6823 |
Patrick J. Culligan | 29 | 72 | 2962 |
Joel R. Rosh | 27 | 92 | 5189 |
Michael L. Gruber | 24 | 45 | 4877 |
Linda D. Gillam | 20 | 61 | 1895 |
Eric D. Whitman | 19 | 48 | 2576 |
Elizabeth A. Eckman | 19 | 33 | 3743 |
Brian M. Slomovitz | 16 | 75 | 1595 |